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PLK (Polo-like kinase) inhibitors, such as BI-2536, have
been reported to suppress IFNB (encoding IFNβ, interferon
β) gene transcription induced by ligands that activate TLR3
(Toll-like receptor 3) and TLR4. In the present study, we
found that BI-2536 is likely to exert this effect by preventing
the interaction of the transcription factors IRF3 (interferon-
regulatory factor 3) and c-Jun with the IFNB promoter, but
without affecting the TBK1 {TANK [TRAF (tumour-necrosis-
factor-receptor-associated factor)-associated nuclear factor κB
activator]-binding kinase 1}-catalysed phosphorylation of IRF3
at Ser396, the dimerization and nuclear translocation of IRF3 or the
phosphorylation of c-Jun and ATF2 (activating transcription factor
2). Although BI-2536 inhibits few other kinases tested, it interacts
with BET (bromodomain and extra-terminal) family members and
displaces them from acetylated lysine residues on histones. We
found that BET inhibitors that do not inhibit PLKs phenocopied
the effect of BI-2536 on IFNB gene transcription. Similarly, BET
inhibitors blocked the interaction of IRF5 with the IFNB promoter
and the secretion of IFNβ induced by TLR7 or TLR9 ligands in
the human plasmacytoid dendritic cell line GEN2.2, but without
affecting the nuclear translocation of IRF5. We found that the
BET family member BRD4 (bromodomain-containing protein 4)
was associated with the IFNB promoter and that this interaction
was enhanced by TLR3- or TLR4-ligation and prevented by BI-
2536 and other BET inhibitors. Our results establish that BET
family members are essential for TLR-stimulated IFNB gene
transcription by permitting transcription factors to interact with
the IFNB promoter. They also show that the interaction of the
IFNB promoter with BRD4 is regulated by TLR ligation and that
BI-2536 is likely to suppress IFNB gene transcription by targeting
BET family members.
Key words: BI-2536, bromodomain and extra-terminal, histone,
interferon, Polo-like kinase, Toll-like receptor.
INTRODUCTION
The interaction of viral dsRNA or bacterial LPS (lipopolysac-
charide) with TLR3 (Toll-like receptor 3) or TLR4 respectively
activates a signalling network that induces the production of
IFNβ (interferon β, encoded by the IFNB gene). The activation
of these receptors leads to the recruitment of the adaptor
protein, TRIF [Toll/IL-1R (interleukin 1 receptor) domain-
containing adaptor inducing IFNβ], which triggers the activation
of TBK1 {TANK [TRAF (tumour-necrosis-factor-receptor-
associated factor)-associated nuclear factor κB activator]-binding
kinase 1} complexes by a mechanism that is not yet understood.
Once activated, TBK1 complexes catalyse the phosphorylation of
IRF3 (interferon-regulatory factor 3), which is followed by the
dimerization of IRF3 and its translocation to the nucleus, where
it binds to IFNB promoters to stimulate IFNB gene transcription
[1–6]. The production of IFNβ by the TLR3–TRIF pathway is
required for host defence against many viruses in mice, such
as cytomegalovirus [7], and in humans is essential for protective
immunity against HSV1 (herpes simplex virus 1) and HSE (HSV1
encephalitis). HSE, a rare and potentially fatal disease of the
CNS (central nervous system), is caused by mutations in genes
encoding components of the TLR3 signalling network, such as
TRIF, TBK1, IRF3 and TLR3 itself [8–10].
The first traces of IFNβ formed by the TLR3 pathway
bind to the Type1 interferon receptor (IFNAR), activating the
JAK (Janus kinase) family members JAK1 and TYK2 (tyrosine
kinase 2), which phosphorylate STAT1 (signal transducer and
activator of transcription 1) and STAT2 [11]. These proteins
form heterodimers that associate with IRF9 to form the ISGF3
(interferon-stimulated gene factor 3) complex, which binds to
ISREs (interferon-stimulated response elements) in the promoters
of ISGs (interferon-stimulated genes). This leads to increased
expression of hundreds of proteins to mount an antiviral state
within the cell. The ISGs include IRF7 [12], which can stimulate
IFNB gene transcription either alone or as a heterodimer with IRF3
[13,14]. IRF7 also stimulates transcription of the genes encoding
IFNα (interferon α), which can also activate the IFNAR. IRF7
therefore drives a positive-feedback loop that amplifies IFNβ
production after prolonged exposure to viral dsRNA [14,15].
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The PLKs (Polo-like kinases) have essential roles in cell
division [16], and PLK1 is highly expressed in a variety of
cancers [17–19], where it is associated with a poor prognosis.
For this reason, specific PLK inhibitors have been developed
that are undergoing clinical trials, such as BI-2536 [20], which
does not inhibit several hundred other protein kinases that
have been tested [21,22]. It was therefore surprising when BI-
2536 and some other PLK inhibitors were reported to suppress
the production of Ifnb mRNA and the transcription of some
ISGs in primary BMDCs (bone-marrow-derived dendritic cells)
stimulated with the dsRNA-mimetic poly(I:C) or LPS, or infected
with VSV (vesicular stomatitis virus). Similar effects were
observed in BMDCs from IFNAR-knockout mice, indicating that
they occurred independently of the positive-feedback loop [23].
These intriguing observations led us to investigate how BI-2536
might be controlling IFNβ production. In the present paper, we
report the results of these studies, which have revealed that this
compound exerts its effects in a way that was not anticipated at
the outset of this investigation.
MATERIALS AND METHODS
Materials
Poly(I:C) was purchased from Invivogen, LPS (Escherichia coli
strain O5:B55) was from Alexis Biochemicals and IFNβ was
from R&D Systems. BI-2536 was purchased from Axon. The
BRD4 (bromodomain-containing protein 4) inhibitors JQ1, I-
BET and I-BET151 were gifts from Dr James Bradner (Dana
Farber Cancer Institute, Boston, MA, U.S.A.), whereas the TBK1
inhibitor MRT67307 was synthesized by Dr Natalia Shpiro (MRC
Protein Phosphorylation and Ubiquitylation Unit, University of
Dundee, Dundee, U.K.). The JNK1/2 (c-Jun N-terminal kinase
1/2) inhibitor JNK-IN-8 has been described previously [24]. The
JAK inhibitor ruxolitinib was purchased from ChemieTek. The
TLR7 agonist CL097 and the TLR9 agonist ODN1826 were
purchased from Invivogen.
Antibodies
Antibodies were raised in sheep against full-length BRD4 (sheep
number S698D) and c-Jun (sheep number 702A) expressed in
E. coli as GST-fusion proteins and the antiserum was affinity-
purified against each antigen coupled covalently to agarose.
The fourth bleed (sheep 698D) and second bleed (sheep 702A)
were used for the studies reported in this paper. The anti-IRF5
antibody was raised in sheep (sheep S485D) as described in [25].
Antibody from the third bleed was used for all experiments.
Phospho-specific antibodies recognizing IRF3 phosphorylated
at Ser396 (catalogue number 4947), STAT1 phosphorylated
at Tyr701 (catalogue number 9171), TBK1 phosphorylated at
Ser172 (catalogue number 5483), ATF2 (activating transcription
factor 2) phosphorylated at Thr69/Thr71 (catalogue number
9225), c-Jun phosphorylated at Ser73 (catalogue number 9164)
and antibodies recognizing all forms of STAT1 (catalogue
number 9172), TBK1 (catalogue number 3013), GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) (catalogue number
2118) and control IgG (catalogue number 2729) were from
Cell Signaling Technologies. The phospho-specific antibody
recognizing JNK1/2 phosphorylated at Thr183/Thr185 (catalogue
number 44682G) and the antibody recognizing all forms of
IRF3 (catalogue number 51-3200) were from Invitrogen. Alexa
Fluor® 568-conjugated rabbit secondary antibody (catalogue
number A10042) and Alexa Fluor® 488-conjugated sheep
secondary antibody (catalogue number A11015) were from
Life Technologies. Rabbit secondary antibodies conjugated to
horseradish peroxidase were from Pierce (catalogue number
31460).
Cell culture, cell lysis and immunoblotting
RAW264.7 macrophages (hereafter referred as RAW cells) and
the human plasmacytoid dendritic cell line Gen2.2 (hereafter
called Gen2.2 cells) were cultured as described in [25,26]. After
stimulation with the ligands, the cells were washed with PBS and
lysed with ice-cold lysis buffer [50 mM Tris/HCl (pH 7.5), 1 mM
EGTA, 1 mM EDTA, 1% (v/v) Triton X-100, 1 mM sodium
orthovanadate, 50 mM NaF, 5 mM sodium pyrophosphate, 0.27 M
sucrose, 10 mM sodium 2-glycerophosphate, 0.2 mM PMSF and
1 mM benzamidine]. The lysates were centrifuged at 15000 g
for 15 min at 4 ◦C, and the supernatant, termed cell extract,
was removed. Protein concentrations were determined using the
Bradford assay. An aliquot of cell extract (20 μg of protein) was
denatured in SDS, subjected to SDS/PAGE and immunoblotted
as described in [27].
Immunofluorescence microscopy
Immunofluorescence was carried out as described previously [28].
The cells were fixed in 4% (v/v) formaldehyde, permeabilized
with 0.2% Triton X-100 in PBS (pH 7.4) and stained with an
antibody recognizing all forms of IRF3 followed by Alexa Fluor®
568-conjugated secondary antibody. The cells were mounted
using ProLong antifade reagent with DAPI (Molecular Probes,
P-36931), and the images were collected on a laser-scanning
confocal microscope (Zeiss LSM 700) with ten fields collected
per coverslip. Images were quantified using the Volocity program
(PerkinElmer). Nuclei were identified using the DAPI-stained
channel while the mean intensity of IRF3 (red channel) in the
nuclear region was measured. For each field, the mean nuclear
intensity was calculated and used to calculate the overall mean
nuclear intensity.
Gen2.2 cells were incubated for 1 h with inhibitors, and then
stimulated for an additional 1 h with agonists. The cells were
fixed for 10 min in 4% (v/v) formaldehyde and 50000 cells
were centrifuged into pre-coated slides (Thermo Scientific). The
cells were permeabilized by incubation with methanol for 10 min
at − 20 ◦C, blocked for 1 h with 0.5% fish gelatin (Sigma–
Aldrich) and 0.1% Tween 20 in PBS, then incubated for 16 h
at 4 ◦C with an anti-IRF5 antibody (2 μg/ml) [25] and washed
with 0.1% Tween 20 in PBS at 21 ◦C. After incubation for 1 h at
21 ◦C with a secondary antibody (Alexa Fluor® 488-conjugated;
1:1000 dilution) and counterstaining with DAPI (0.05 μg/ml) to
reveal nuclei, images were acquired using a Delta Vision DV3
deconvolution microscope with an oil-immersion ×63 objective
lens and images were processed using OMERO. Images presented
correspond to one stack from deconvolved three-dimensional
images.
Native polyacrylamide gel electrophoresis
Gels cast without SDS were pre-run for 30 min at 40 mA in 25 mM
Tris/HCl and 192 mM glycine with and without 1% (w/v) sodium
deoxycholate in the cathode and anode chamber respectively.
Samples without SDS or a reducing agent were applied to the
gel, electrophoresed for 60 min at 25 mA and transferred on to
PVDF membranes. The membranes were blocked as described
c© 2015 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted
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above for SDS/PAGE and immunoblotted using the antibody that
recognizes all forms of IRF3.
mRNA measurements
RNA was extracted from cells using the OMEGA Total
RNA Kit, and 1.0 μg of RNA was reverse-transcribed
using iScript reverse transcriptase and the accompanying
reagents (Bio-Rad Laboratories), according to the manufacturer’s
instructions. qPCR (quantitative PCR) was then performed
as described using the SsoFastTM EvaGreen® Supermix
(Bio-Rad Laboratories). The primers used for measuring
mRNA encoding mouse Ifnb, Isg15 and Cxcl10 [29] and
Il6 [30] have been described. The following primer pair
was used for qPCR of the mouse Rantes (regulated upon
activation, normal T-cell expressed and secreted) gene: Rantes-
forward, 5′-GCTGCTTTGCCTACCTCTCC-3′ and Rantes-
reverse, 5′-ACACTTGGCGGTTCCTTCG-3′. Normalization and
quantification were performed using 18S RNA and the CT
method. All mRNA measurements were performed in triplicate.
Measurement of IFNβ secretion
The level of secreted IFNβ in the cell culture medium was
determined using the Verikine mouse and human IFNβ ELISA
kits (PBL Interferon Source) or the LEGEND MAXTM Mouse
IFN-β ELISA Kit (BioLegend) following the manufacturer’s
protocol.
ChIP assay
RAW cells (1.5×107) cells or Gen2.2 cells (1.6×107 cells) were
incubated for 1 h with inhibitors and stimulated with LPS or
poly(I:C) (RAW cells) or CL097 (Gen2.2 cells) (see the Results
section). The cells were then treated for 10 min at 20 ◦C with
1% (w/v) formaldehyde and cross-linking was terminated by
adding glycine to 0.125 M followed by washing the cells with
PBS. The cells were lysed in 50 mM Tris/HCl (pH 8.1), 10 mM
EDTA, 1 mM PMSF, CompleteTM protease inhibitor cocktail
(Roche) and 1% (w/v) SDS. Chromatin was sheared by eight
15 s bursts of sonication at 4 ◦C using a VibraCell sonicator
(Sonics) at 50% power (RAW cells) or by fifteen 30 s bursts
at 4 ◦C using a waterbath sonicator at high power (Bioruptor,
Diagenode) (Gen2.2 cells). Samples were centrifuged at 15000 g
for 10 min at 4 ◦C, and the soluble chromatin fraction was diluted
10-fold in 20 mM Tris/HCl (pH 8.1), 2 mM EDTA, 150 mM NaCl
and 1% (v/v) Triton X-100, and pre-cleared by incubation for 2 h
at 4 ◦C with Protein G–Sepharose and 2 μg of sheared salmon
sperm DNA. After retaining 10% of the sample for use as an
input control, the rest of the chromatin fraction was incubated
for 16 h at 4 ◦C with 5 μg of acetylated histone H3 (Millipore),
5 μg of anti-BRD4 antibody or 5 μg of anti-IRF3 antibody (Santa
Cruz Biotechnology) or 2 μg of anti-IRF5 antibody or 5 μg of
control IgG. To isolate the immune complexes, the samples were
incubated for 1 h at 4 ◦C on a rotating platform with 30 μl of
Protein G-Sepharose. After brief centrifugation and washing once
in 20 mM Tris/HCl (pH 8.0), 2 mM EDTA, 150 mM NaCl, 0.1%
SDS and 1% (v/v) Triton X-100, once in the same buffer plus
0.5 M NaCl, once in 10 mM Tris/HCl (pH 8.0), 1 mM EDTA,
0.25 M LiCl, 1% (v/v) Nonidet P40 and 1% (w/v) sodium
deoxycholate, and twice in 10 mM Tris/HCl (pH 8.0) and 1 mM
EDTA, the immunoprecipitates were eluted with 0.1 M NaHCO3
and 1% (w/v) SDS, and cross-linking was reversed by incubation
for 16 h at 65 ◦C in 0.2 M NaCl. Samples were digested with
Proteinase K (Qiagen) for 1 h at 45 ◦C, and DNA was purified
using a Spin Column PCR Purification Kit (NBS Bio). Purified
immunoprecipitated DNA and input DNA were analysed by
quantitative PCR using the SsoFastTM EvaGreen® Supermix. The
primers for amplification of the mouse Ifnb promoter [29] and
the human IFNB promoter [31] have been described. The qPCR
data were analysed and presented using the Percentage Input
{100×2[Input(CT) − IP(CT)]} method.
RESULTS
BI-2536 blocks Ifnb mRNA production without affecting the
phosphorylation, dimerization or nuclear translocation of IRF3
We confirmed earlier observations that BI-2536 prevents the LPS-
stimulated secretion of IFNβ when included in the cell culture
medium at a concentration of 1.0 μM or higher (Supplementary
Figure S1A). Consistent with these observations, the production
of Ifnb mRNA induced by either poly(I:C) (Supplementary Figure
S1B) or LPS (Supplementary Figure S1C) was also prevented by
the inclusion of BI-2536 (1.0 μM). In contrast, BI-2536 did not
suppress the poly(I:C)-stimulated (Figure 1A) or LPS-stimulated
(Figure 1B) activation of TBK1, as judged by the phosphorylation
of its activation loop at Ser172 [32], or the phosphorylation
(Figures 1A–1D), dimerization (Figures 1E and 1F) and nuclear
translocation (Supplementary Figures S1D and S1E) of IRF3. In
contrast, MRT67307, a potent and relatively specific inhibitor of
TBK1 [33], blocked IRF3 phosphorylation (Figures 1C and 1D)
and dimerization (Figures 1E and 1F) as expected. Our results
disagree with the previous study in which BI-2536 was reported
to prevent the nuclear translocation of IRF3 [23]. The compound
JQ1, an inhibitor of the BET family of bromodomain inhibitors,
which was included in these experiments for reasons discussed
below, phenocopied the effects of BI-2536 (Figure 1).
The inclusion of BI-2536 in the cell culture medium had no
effect on the IFNβ-stimulated phosphorylation of STAT1 at Tyr701
(Supplementary Figure S2A), indicating that it does not affect the
interaction of IFNβ with IFNAR, or the activation or activity of
JAK1 or TYK2. These findings indicated that the initial steps in
the positive-feedback loop (see the Introduction) were unaffected
by BI-2536.
We have reported that the poly(I:C)-stimulated production of
Ifnb mRNA in primary bone-marrow-derived macrophages is
unaffected up to 2 h by the potent and specific JAK inhibitors
ruxolitinib and tofacitinib [29], whereas the late surge in Ifnb
mRNA production that occurs after more prolonged stimulation
with poly(I:C) is blocked by these compounds [29]. We also
found that the LPS-stimulated production of Ifnb mRNA was
essentially independent of the positive-feedback loop since it
was unaffected by the JAK inhibitors at any time point [29]. These
findings were confirmed in the RAW macrophage-like cell line in
the present study. The poly(I:C)- or LPS-dependent increase in
Ifnb mRNA production after 2 h was suppressed by BI-2536, but
not affected significantly by ruxolitinib (Supplementary Figures
S2B and S2C) at concentrations that completely blocked the JAK-
catalysed phosphorylation of STAT1 at Tyr701 (Supplementary
Figures S2D and S2E). Taken together, the results presented
in Figure 1 and Supplementary Figures S1 and S2 indicate
that BI2536 prevents poly(I:C)- or LPS-stimulated Ifnb mRNA
production by a novel mechanism that is independent of either
the classical TBK1–IRF3 signalling pathway or the JAK/TYK2–
STAT1/2-driven positive-feedback loop.
c© 2015 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted
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Figure 1 BI-2536 and JQ1 do not impair the poly(I:C)- or LPS -stimulated activation of TBK1 or the phosphorylation and dimerization of IRF3
(A and B) RAW cells were incubated for 1 h with the indicated concentrations of BI-2536, and then stimulated for 2 h without ( − ) or with ( + ) poly(I:C) (10 μg/ml) (A) or LPS (100 ng/ml) (B). Cell
lysates (25 μg of protein) were subjected to SDS/PAGE, transferred on to PVDF membranes and immunoblotted with antibodies that recognize TBK1 phosphorylated at Ser172, IRF3 phosphorylated
at Ser396 and GAPDH as loading control. (C and D) RAW cells were incubated for 1 h without ( − ) or with ( + ) 2.0 μM of the TBK1 inhibitor MRT67307, 1.0 μM BI-2536 or 1.0 μM JQ1, and then
stimulated for 1 h with poly(I:C) (10 μg/ml) (C) or LPS (100 ng/ml) (D). Cell extracts were immunoblotted with the anti-IRF3 and anti-GAPDH antibodies used in (A) and (B). Similar results were
obtained in two other independent experiments for (A)–(D). (E and F) RAW cells were incubated for 1 h without ( − ) or with ( + ) 2.0 μM MRT67307, 1.0 μM BI-2536 or 1.0 μM JQ1 and then
stimulated with poly(I:C) (10 μg/ml) (E) or LPS (100 ng/ml) (F) for the times indicated. The cell lysates (10 μg of protein) were subjected to native PAGE to separate the monomeric and dimeric
forms of IRF3, which were detected by immunoblotting with an antibody that recognizes all forms of IRF3.
Figure 2 Poly(I:C)- and LPS-stimulated Ifnb gene transcription and IFNβ secretion is inhibited by BI-2536 and JQ1
RAW cells were incubated for 1 h without ( − ) or with ( + ) 1.0 μM JQ1 or 1.0 μM BI2536 and then stimulated for 8 h without ( − ) or with ( + ) poly(I:C) (10 μg/ml) (A and C) or for 4 h without
( − ) or with ( + ) LPS (100 ng/ml) (B and D). At each time point, the total RNA was extracted from the cells and Ifnb mRNA was quantified by qPCR (A and B) and the concentration of IFNβ in the
cell culture medium was determined by ELISA (C and D). Results are means + S.E.M for triplicate determinations. (A) and (B) show the fold increase in mRNA levels relative to the values measured
in cells that had not been stimulated with LPS or poly(I:C).
c© 2015 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted
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Figure 3 The BRD4 inhibitors I-BET and I-BET151 suppress poly(I:C)- or
LPS-stimulated Ifnb gene transcription in RAW cells
(A) Cells were incubated for 1 h with the indicated concentrations of I-BET151, I-BET or JQ1 and
then stimulated for 2 h without ( − ) or with ( + ) poly(I:C). Total RNA was isolated and IFNB
mRNA levels were quantified by qPCR. (B) As for (A) except that the cells were stimulated for
2 h with LPS (100 ng/ml). Results are mean +− S.E.M. fold increases in mRNA levels relative to
the values measured in cells not stimulated with poly(I:C) or LPS for triplicate determinations.
Similar results were obtained in two independent experiments.
BI-2536 appears to exert its effects on Ifnb gene transcription by
inhibiting BET family members
Although among protein kinases BI-2536 shows a high degree
of specificity for PLK isoforms (see the Introduction), it was
recently reported to bind strongly to BRD4 and other members
of the BET family of proteins [34]. To investigate whether the
effects of BI-2536 might be explained by the interaction of
this compound with one or more BET family members, we
initially compared its effects with those of JQ1, which is a potent
inhibitor of the BET family [35]. We found that, whereas BI-
2536 inhibited PLK1 in vitro with an IC50 value of 4.0 +− 0.2 nM(average of duplicate determinations), JQ1 had no effect on PLK1
activity even at 10 μM, and at 1.0 μM did not inhibit 140 other
protein kinases tested significantly (Supplementary Figure S3).
Nevertheless, like BI-2536, JQ1 suppressed the poly(I:C)- or
LPS-stimulated production of Ifnb mRNA (Figures 2A and 2B,
and Supplementary Figures S2B and S2C) and IFNβ secretion
(Figures 2C and 2D) as effectively as BI-2536, and without
affecting the phosphorylation of IRF3 at Ser396 (Figures 1C
and 1D), or the dimerization (Figures 1E and 1F) and nuclear
translocation (Supplementary Figures S1D and S1E) of IRF3.
Like BI-2536, JQ1 also suppressed the poly(I:C)- or LPS-
stimulated phosphorylation of STAT1 at Tyr701 (Supplementary
Figures S2D and S2E). Two other BET inhibitors, I-BET and I-
BET151 [36], which are structurally unrelated to JQ1 or BI-2536,
also prevented the poly(I:C)- or LPS-stimulated production of
Ifnb mRNA (Figures 3A and 3B). Like JQ1, these compounds
also had little effect on PLK1 activity with 10% inhibition
(I-BET151) and 25% inhibition (I-BET) only at 1.0 μM
in vitro.
BET inhibitors impair the recruitment of IRF3, c-Jun and BRD4 to
the Ifnb promoter
BET family members contain two bromodomains [35] and bind
to pairs of acetylated lysine residues in the histone components of
chromatin. BRD4 has been reported to recruit the pTEFb (positive
transcription elongation factor B) kinase complex to transcription
start sites, where it phosphorylates and activates RNA polymerase
II to initiate transcription [37–40]. This can explain why some
gene transcription programmes are inhibited when BET family
members are displaced from chromatin by compounds that bind
to their bromodomains.
Interestingly, we found that the poly(I:C)- or LPS-stimulated
association of IRF3 with the Ifnb promoter was suppressed by
JQ1, I-BET151 (Figures 4A and 4B) and BI-2536 (Supplementary
Figure S4A), suggesting that the interaction of one or more BET
family members with acetylated histones permits IRF3 to access
the Ifnb promoter. To investigate whether BRD4 was associated
with the Ifnb gene promoter, we carried out further ChIP assays in
which we immunoprecipitated BRD4 or control IgG and studied
whether Ifnb gene promoter sequences could be detected in the
immunoprecipitates. We found not only that these sequences were
present in the immunoprecipitates, but also that the amount of
Ifnb promoter DNA present in the immunoprecipitated BRD4
was increased by stimulation with poly(I:C) (Figure 4C) or
LPS (Figure 4D). Importantly, this increase did not occur
if the macrophages were incubated with the BET inhibitors
I-BET151 or JQ1 (Figures 4E and 4F) or with BI2536
(Supplementary Figure S4B) before stimulation with poly(I:C) or
LPS.
To check whether BET family members mediate IRF3
recruitment specifically or whether they have a more general
effect on promoter accessibility, we also studied their role in
recruiting c-Jun to the Ifnb promoter. c-Jun is a component of the
AP1 (activator protein 1) transcription factor, which is reported
to be a component of the IFNβ enhanceosome [41,42]. We found
that the interaction of c-Jun with the Ifnb promoter was increased
by stimulation with poly(I:C) or LPS and that basal, as well as
stimulated, interaction with the Ifnb promoter was suppressed by
either BI-2536 or JQ1 (Figures 5A and 5B). Therefore blocking
the interaction of BET family members with acetylated proteins
appears to have a more global effect on the accessibility of the
Ifnb promoters to transcription factors.
Control experiments showed that neither BI-2536 nor JQ1
suppressed the poly(I:C)- or LPS-stimulated phosphorylation of
JNK1/2 and that, in contrast with the covalent JNK inhibitor JNK-
IN-8, they did not inhibit the phosphorylation of c-Jun and ATF2
(Figures 5C and 5D). Therefore BI-2536 and JQ1 do not suppress
Ifnb gene transcription by inhibiting a component of the signalling
pathway that leads to the activation of JNK and phosphorylation
of its substrates.
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Figure 4 The poly(I:C)- or LPS-induced association of IRF3 and BRD4 with the Ifnb promoter is prevented by BET inhibitors
RAW cells were incubated for 1 h, with or without JQ1 or I-BET151, then stimulated for the times indicated with either 10 μg/ml poly(I:C) (A, C and E) or 100 ng/ml LPS (B, D and F). They were
then cross-linked and lysed, and the chromatin was sheared by sonication. ChIP was performed using antibodies that recognize IRF3 (A and B) or BRD4 (C–F). In all panels, the enrichment of the
Ifnb promoter was measured by qPCR, normalized to input (see the Materials and methods section). Results are means + S.E.M. for triplicate determinations. IP, immunoprecipitation.
Influence of BI-2536 and JQ1 on the transcription of other poly(I:C)-
and LPS-regulated genes
Since BI-2536 and JQ1 blocked IFNβ production by preventing
the interaction of transcription factors with the Ifnb promoter, it
was of interest to examine the effects of these compounds on
the transcription of other poly(I:C)- and LPS-regulated genes.
Similar to Ifnb gene transcription, we found that BI-2536 and
JQ1 suppressed the transcription of Il6 (Supplementary Figures
S5A and S5B), suggesting that BET family members are also
important in regulating the accessibility of transcription factors to
the Il6 promoter. However, the effects of these compounds on the
transcription of Rantes (Supplementary Figure S5C and S5D)
were modest, suggesting that other bromodomain-containing
proteins may control the transcription of this gene.
BET inhibitors block the TLR7- and TLR9-dependent production of
IFNβ without affecting the nuclear translocation of IRF5
We recently reported that the TLR7-stimulated production of
IFNβ in the human plasmacytoid dendritic cell line Gen2.2
occurs via an analogous pathway in which IKKβ [IκB (inhibitor
of nuclear factor κB) kinase β] phosphorylates IRF5 at Ser462,
inducing its dimerization and translocation to the nucleus where
it stimulates Ifnb gene transcription [25]. Similar to the TLR3–
TBK1–IRF3 pathway, we found that BI-2536, JQ1 and I-BET151
blocked the TLR7- or TLR9-stimulated secretion of IFNβ in
Gen2.2 cells (Figures 6A and 6B), without affecting the TLR-
stimulated translocation of the endogenous IRF5 to the nucleus
(Figure 6C). In contrast, BI-605906 blocked nuclear translocation
of IRF5 as expected (Figure 6C). The antibody employed in
these studies recognized IRF5 specifically because the signal
was abolished by the siRNA knockdown of IRF5 (Supplementary
Figure S6). We also found that stimulation with the TLR7 agonist
CL097 induced the interaction of IRF5 with the Ifnb promoter
and that this was blocked by either BI-2536 or JQ1 (Figure 6D).
DISCUSSION
The work described in the present paper was prompted by a report
that inhibitors of the PLK subfamily of protein kinases, such
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Figure 5 The poly(I:C)- or LPS-induced association of c-Jun with the Ifnb promoter is prevented by BET inhibitors without inhibiting the phosphorylation of
c-Jun or ATF2
(A and B) The experiment was performed as in Figure 4 except that an anti-c-Jun antibody was used. (C and D) RAW cells were incubated for 1 h with 1.0 μM BI-2536, 1.0 μM JQ1 or 10 μM of the
JNK inhibitor JNK-IN-8 and then stimulated for 1 h with 10 μg/ml poly(I:C) (C) or for 30 min with 100 ng/ml LPS (D). The cells were lysed and 20 μg of cell extract protein was denatured in SDS
and subjected to SDS/PAGE followed by immunoblotting with antibodies that recognize the phosphorylated forms of JNK1/2, c-Jun and ATF2 as well as GAPDH. JNK-IN-8 binds covalently to JNK1
and JNK2 leading to a small decrease in their electrophoretic mobilities. IP, immunoprecipitation.
as BI-2536, prevented Ifnb gene transcription induced by LPS,
poly(I:C) or viral infection [23], raising the question of how these
kinases might control this process. We confirmed that BI-2536
suppressed Ifnb gene transcription induced by poly(I:C) or LPS,
but found that it occurred independently of the classical TRIF-
dependent pathway in which the activation of TBK1 is followed
by the phosphorylation and dimerization of the transcription
factor IRF3 (Figure 1 and Supplementary Figure S1). Moreover,
and in contrast with the earlier report [23], we found that BI-
2536 did not inhibit the translocation of IRF3 to the nucleus
(Supplementary Figure S1D). We also established that BI-2536
was exerting its effect independently of the positive-feedback
loop, which is driven by IFNβ via the JAK1/TYK2–STAT1/2
pathway (Supplementary Figure S2). On the other hand, BI-
2536 did prevent the interaction of activated IRF3 (Figure 4)
or the transcription factor c-Jun (Figure 5) with the Ifnb promoter,
indicating that this compound was exerting its effect at the level
of the Ifnb promoter distal to the activation of IRF3.
BI-2536 is a rather specific kinase inhibitor that does not
affect several hundred other protein kinases that have been
tested. However, after the experiments described in the preceding
paragraph had been completed, we learned that a number of
protein kinase inhibitors, including BI-2536, bind to the first
bromodomain of the BET family member BRD4 and displace
BRD4 and other BET family members from chromatin. These
results, together with the three-dimensional structure of the
BRD4–BI-2536 complex, have subsequently been published [34].
The two bromodomains of BET family members interact with
pairs of acetylated lysine residues on histones in chromatin and
are thought to facilitate specific gene transcription by recruiting
other proteins to gene promoters. For example, BRD4 recruits
the pTEFb kinase complex to transcription start sites, where
it phosphorylates and activates RNA polymerase II to initiate
transcriptional elongation [37–40]. These findings led us to study
other compounds that interact with the bromodomains of BET
family members, and which are structurally unrelated to BI-2536
or each other, and do not inhibit PLKs. We found that, similar
to BI-2536, these compounds also suppressed TLR3-, TLR4-,
TLR7- or TLR9-stimulated Ifnb gene transcription and secretion
(Figures 2, 3 and 6) without affecting the activation or nuclear
translocation of IRF3 (Figure 1 and Supplementary Figure S1D)
or IRF5 (Figure 6). These results suggest that BI-2536 blocks
Ifnb gene transcription by inhibiting BET family members and
not the PLK subfamily of protein kinases. Consistent with this
notion, we found that BI-2536 or BET inhibitors suppressed the
interaction of IRF3 or c-Jun (Figures 4 and 5) or IRF5 (Figure 6)
with the Ifnb promoter and that BRD4 was associated with the Ifnb
promoter (Figures 4C and 4D). Thus BET family members have an
important general role in permitting accessibility of transcription
factors to the Ifnb promoter. BET family members appear to have
a similar role in regulating the Il6 promoter, but not the Rantes
promoter (Supplementary Figure S5).
Interestingly, poly(I:C) and LPS enhanced the association of
BRD4 with the Ifnb promoter and this was prevented by the
bromodomain inhibitors (Figures 4C–4F). To our knowledge,
this is the first report that the association of a BET family
member with a gene promoter is regulated by ligands that
activate TLRs. This increased association of BRD4 with the
Ifnb promoter could be explained by an increase in histone
acetylation, which in turn could arise from increased HAT
(histone acetyltransferase) activity and/or decreased HDAC
(histone deacetylase) activity. Importantly, the HAT activities of
CBP [CREB (cAMP-response-element-binding protein)-binding
protein] and PCAF (p300/CBP-associated factor) are reported
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Figure 6 BET inhibitors block IFNβ production in Gen2.2 cells by suppressing the interaction of IRF5 with the Ifnb promoter and not by preventing the nuclear
translocation of IRF5
(A and B) Gen2.2 cells were incubated for 1 h with or without BI-2536 (1.0 μM), JQ1 (1.0 μM) or I-BET151 (1.0 μM) and then stimulated for 8 h with CL097 (1.0 μg/ml) (A) or for 12 h with
ODN1826 (1.0 μM) (B). The concentration of IFNβ in the culture medium was measured by ELISA. Results are means + S.D. from two independent experiments each performed in duplicate. (C)
Gen2.2 cells were incubated for 1 h with or without BI-2536 (1.0 μM), JQ1 (1.0 μM), I-BET151 (1.0 μM) or BI-605906 (5.0 μM) and then stimulated for 1 h with CL097. Staining with anti-IRF5,
or DAPI to reveal nuclei, followed by deconvolution microscopy was performed as described in the Materials and methods section. (D) Gen2.2 cells were incubated for 1 h with BI-2536 (1 μM)
or JQ1 (1 μM), then stimulated for 1 h with the TLR7 agonist CL097 (1 μg/ml), cross-linked and lysed. Chromatin was sheared by sonication and ChIP was performed using anti-IRF5. The
enrichment of the Ifnb promoter was measured by qPCR, normalizing to input. Results are means + S.D. similar results were obtained in three independent experiments each performed in duplicate.
IP, immunoprecipitation.
to be needed for Ifnb gene transcription [43,44]. Whether TLR
ligands enhance the interaction of BRD4 with the Ifnb promoter
by activating these or other HATs and/or by inhibiting HDACs
is unknown, but viral infection has been reported to induce the
localized hyperacetylation of histones at the Ifnb promoter [45].
Alternatively, or in addition, LPS and poly(I:C) might induce
a modification of BRD4 that enhances its ability to interact
with acetylated histones, or these TLR agonists might stimulate
the synthesis of BRD4 and other BET family members within
cells.
The finding that compounds developed as protein kinase
inhibitors interact strongly with the bromodomains of BET
family members and prevent their interaction with acetylated
lysine residues [34,46] has far-reaching implications. It implies
that many protein kinase inhibitors reported to suppress gene
transcription, or other events dependent on gene transcription,
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may actually exert these effects by inhibiting BET family
members and not protein kinases. The human genome encodes
42 proteins that contain bromodomains (56 bromodomains in
total) and the development of a panel of these bromodomains
will clearly be essential to assess which protein kinase
inhibitors possess these ‘off-target’ effects. The present study
has shown that suppression of TLR3- or TLR4-stimulated
IFNβ production without inhibition of IRF3 phosphorylation
or nuclear translocation, or TLR7- or TLR9-stimulated IFNβ
production without inhibition of IRF5 phosphorylation or nuclear
translocation, could be used as a simple test to check whether a
protein kinase inhibitor is likely to be a BET inhibitor.
The overproduction of IFNβ is a major cause of endotoxaemia
and endotoxic shock in mice, since mice lacking expression of
the genes encoding IFNβ or IFNAR are resistant to LPS-induced
endotoxaemia [12,47,48]. In humans, sepsis causes 1400 deaths
per day worldwide and effective therapies are still lacking [49].
It is therefore of considerable interest that the injection of I-
BET into mice before the induction of septic shock with LPS or
heat-killed Salmonella enterica serotype Typhimurium delayed
or prevented the death of these mice, whereas a single injection of
I-BET administered after LPS had already induced inflammation
overcame this inflammatory condition [36]. BI-2536 and the
closely related compound BI-6727 have passed Phase 1 clinical
trials and entered Phase 2 trials for the treatment of cancer
[50], and only moderate side effects of these compounds have
been reported [51,52]. These compounds, as well as other BET
inhibitors, therefore merit investigation as potential therapies for
diseases and conditions caused by the hyperproduction of IFNβ,
which include the lethal effects of flu virus as well as sepsis.
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